
Cassava Sciences Inc is a biotechnology company that has been making waves in the market with its innovative treatments for neurodegenerative diseases.
The company's stock, CASV, has seen significant fluctuations in recent times, with a high of $45.50 and a low of $13.50.
Cassava Sciences Inc reported a net loss of $34.8 million in the second quarter of 2022, which is a significant increase from the same period in 2021.
The company's revenue has been steadily increasing, with a total of $1.2 million in the second quarter of 2022, up from $434,000 in the same period in 2021.
Expand your knowledge: Ventas Inc Stock Price
Stock Information
Cassava Sciences Inc's financial performance is a crucial aspect to consider when evaluating its stock. The company's revenue and net income figures are available in its past financial reports.
You can find Cassava Sciences Inc's past financial performance, including revenue and net income, by checking its past financial reports. This information can help you make informed decisions about investing in the company's stock.
Additional reading: Cassava Sciences Stock Quote
Cassava Sciences Inc's market value is also an essential factor to consider. The company's current market value is available for review.
To get a better understanding of Cassava Sciences Inc's market value, you can check its current market value, which is a top-level summary of its past and current market value.
On a similar theme: Arihant Capital Market Share Price
Company Updates
Cassava Sciences is providing an update on its business, and it's worth noting that the company is expecting top-line data from its Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer's disease.
This data is expected to be released late in the first quarter or early in the second quarter of 2025, which could have a significant impact on the company's stock performance.
Readers also liked: S B I Card Share Price
Business Update
Cassava Sciences is providing a business update that's worth noting. Topline data from the Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer's disease is expected late first-quarter/early second-quarter 2025.
This update gives us a better idea of the study's timeline. The study's focus is on simufilam, a treatment for mild-to-moderate Alzheimer's disease.
We can expect to hear more about the study's results soon.
Past Events

Cassava Sciences has had a string of Annual General Meetings, with the most recent one taking place on 05/09/2024.
The company has also released several Earnings Reports, with the most recent one reporting an actual EPS of -0.500 USD on 02/28/2024.
We can see a pattern of declining EPS over the years, with the lowest being -2.320 USD at the Annual General Meeting on 05/09/2024.
Here's a list of Cassava Sciences' recent Earnings Reports:
The company's Annual General Meetings have also seen a decline in EPS, with the lowest being -1.900 USD on 05/04/2023.
Frequently Asked Questions
Is cassava stock a buy or sell?
Cassava Sciences stock is considered a buy by Zacks, with a potential above-average return expected in the next few months. This rating is based on Zacks' proprietary data and a Zacks Rank of 2.
What is the prediction for cassava science?
There is no prediction for cassava science as the text appears to be about a company named SAVA, not a scientific field. The provided information is a financial forecast for the company SAVA.
What is the price target for SAVA in 2025?
The estimated price target for SAVA is between $2.00 and $116.00 USD, with a median estimate of $59.00 USD. Analysts' predictions suggest a wide range of possible prices for SAVA in 2025.
Featured Images: pexels.com